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Abstract The fifth type GalNAcK2,6-sialyltransferase
(mST6GalNAc V) was cloned from a mouse brain cDNA
library. mST6GalNAc V exhibited type II transmembrane
topology containing a polyglutamine repeat, which showed
42.6% and 44.8% identity to mouse ST6GalNAc III and IV,
respectively. Northern blot analysis revealed that the mST6Gal-
NAc V gene was specifically expressed in forebrain and
cerebellum. mST6GalNAc V exhibited GD1K synthetic activity
from GM1b the same as mST6GalNAc III and IV. The activity
ratio of GM1b toward fetuin and the expression pattern were
completely different among the three ST6GalNAcs. Interest-
ingly, the polyglutamine repeat number was different from that
of inbred mice. We report the first glycosyltransferase with a
polymorphic polyglutamine repeat.
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1. Introduction
Carbohydrate antigens containing sialic acids appear in the
course of carcinogenesis [1]. Their appearance seems to corre-
late with the characteristics of cancers such as poor prognosis
or metastatic potential [2^5]. Sialyl-Tn (STn) antigen is char-
acterized as one of the cancer-associated carbohydrate anti-
gens, whose expression has been correlated with poor prog-
nosis in gastric cancer patients [4,5]. To elucidate the function
of STn antigen in the progression of gastric cancer, as a ¢rst
step, we recently cloned STn antigen synthetic enzyme (human
GalNAcK2,6-sialyltransferase I (hST6GalNAc I)) from gastric
mucosa [6]. The gene expression of hST6GalNAc I was well
correlated with STn antigen positive gastric intestinal meta-
plasia and gastric cancer. The result clearly indicated that
hST6GalNAc I takes part in STn antigen synthesis in gastric
mucosa. However, further analysis of gene expression in other
organs revealed little correspondence with the expression of
the hST6GalNAc I gene and STn antigen [7], suggesting the
occurrence of unidenti¢ed GalNAcK2,6-sialyltransferases.
Thus, we tried molecular cloning of a new GalNAcK2,6-sialyl-
transferase. We performed BLAST analysis on a mouse ex-
pressed sequence tags (EST) database with the amino acid
sequence of sialyl motifs L and S of the mST6GalNAc family
and identi¢ed two clones containing a sequence most similar
to ST6GalNAc IV in the mST6GalNAc family. We report
here the substrate speci¢city and gene expression pattern of
the newly cloned ST6GalNAc V, which is a new candidate for
GD1K antigen synthase.
2. Materials and methods
2.1. Materials
Fetuin, asialofetuin, bovine submaxillary mucin, bovine submaxil-
lary asialomucin, K1-acid glycoprotein, holotransferrin, GM1a,
GD1a, GD1b, GT1b, GM3, paragloboside, asialo-GM1, CMP-Neu-
Ac, and Triton CF-54 were purchased from Sigma Chemical Co. (St.
Louis, MO, USA). CMP-[14C]NeuAc (300 mCi/mmol) was from
Amersham-Pharmacia Japan (Tokyo, Japan). Synthetic primers were
synthesized by Gibco-BRL (Gibco-BRL, Rockville, MD, USA). Re-
striction endonucleases were from New England Bio Labs Inc. (Bev-
erly, MA, USA). HPTLC plate silica gel 60 was purchased from
Merck (Darmstadt, Germany). C3H-HeNCrj (C3H) and C57BL-
6Ncrj (B6-N) were from Charles River Japan, Inc. (Kanagawa, Japan)
and Slc:CD1 (ICR) mice were from SLC, Inc. Japan (Shizuoka, Ja-
pan). C57BL-6J (B6-J) mouse substrain was from Jackson’s Lab.
(Charles River Japan, Inc.). Monoclonal antibody (mAb) KA17 spe-
ci¢c for GD1K [8] (IgM) was kindly gifted by Dr. Y. Hirabayashi
(Laboratory for Glyco Cell Biology, Frontier Research Program,
RIKEN).
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Abbreviations: NeuAc, N-acetylneuraminic acid; GalNAc, N-acetyl-
galactosamine; ST6GalNAcs, GalNAcK2,6-sialyltransferases; ST6-
GalNAc I, GalNAcK2,6-sialyltransferase I (EC 2.4.99.3); ST6GalNAc
II, GalL1,3GalNAc speci¢c GalNAcK2,6-sialyltransferase; ST6Gal-
NAc III, the ¢rst type of NeuAcK2,3-GalL1,3GalNAc speci¢c Gal-
NAc-K2,6-sialyltransferase III (EC 2.4.99.7); ST6GalNAc IV, the sec-
ond type of NeuAcK2,3-GalL1,3GalNAc speci¢c GalNAc-K2,6-
sialyltransferase IV (EC 2.4.99.7); ST3Gal I, GalL1,3GalNAcK2,3-
sialyltransferase (EC 2.4.99.4); CMP-NeuAc, cytidine 5P-monophos-
pho-N-acetylneuraminic acid; ORF, open reading frame; EST, ex-
pressed sequence tags; PCR, polymerase chain reaction; SDS-
PAGE, sodium dodecylsulfate-polyacrylamide gel electrophoresis;
TLC, thin layer chromatography; HPTLC, high performance thin
layer chromatography; mAb, monoclonal antibody; NANase, N-ace-
tylneuraminidase; The nomenclature for gangliosides follows the sys-
tem of Svennerholm [26]; The abbreviated nomenclature for cloned
sialyltransferases follows the system of Tsuji et al. [27]
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2.2. Probe preparation
We performed BLAST analysis on a mouse EST database with
sialyl motifs L and S of ST6GalNAcs for the queries, and clones
AU035329 from brain cDNA library and AA462934 from mammary
gland were expected to contain a homologous sequence in ST6Gal-
NAc IV sialyl motif L. Polymerase chain reaction (PCR) primers 5P
primer YI-1: 5P-CCCAAAATGAAGACCCTGATG-3P and 3P primer
YI-2: 5P-GGCATCATTCATGCGGAATAAC-3P were set on
AU035329 nucleotide sequence to obtain the cDNA fragment with
the reverse transcription polymerase chain reaction (RT-PCR) meth-
od. Template cDNA was synthesized from adult ICR mouse brain
total RNA with the Superscript Preampli¢cation System for First
Strand cDNA Synthesis (Gibco-BRL). It was diluted 50-fold with
H2O, 10 Wl of which was applied for template cDNA. Thus, a total
volume of 50 Wl of PCR reaction mixture consisted of 0.2 WM of the
primer set, YI-1 and YI-2, 10 mM Tris^HCl (pH 8.3), 50 mM KCl,
2.5 mM MgCl2, 0.2 WM of each dNTP, 0.1% Triton X-100, Ampli
Taq Gold (Roche Molecular Systems, Branchburg, NJ, USA) and
10 Wl of the diluted synthesized cDNA. After preheating for 10 min
at 94‡C, 40 cycles of PCR were run for 1 min at 94‡C, 1 min at 60‡C
as an annealing temperature, and 1 min at 72‡C. The ampli¢ed 387 bp
cDNA fragment was subcloned in pCR II vector (pCR II-387bp frag.)
(TA Cloning Kit, Invitrogen, Carlsbad, CA, USA) and puri¢ed with
Qiaprep Spin Miniprep Kit (Qiagen K.K., Tokyo, Japan) to deter-
mine the nucleotide sequence. The NsiI-EcoRI 151 nucleotide frag-
ment without CAG repeat from the pCR II-387bp fragment was used
as a hybridization probe.
2.3. Isolation of cDNA from adult mouse brain cDNA library
The adult mouse brain cDNA library was previously constructed
[9,10]. We performed phage plaque, plaque lift, hybridizing screening,
and in vivo excision according to the instruction manual (Stratagene,
La Jolla, CA, USA).
2.4. Construction of phylogenetic tree of sialyltransferases
The 1005 bp open reading frame (ORF) encoding a protein was
contained in the isolated cDNA clone, U1, whose start codon was
assigned by Kozak consensus sequence. The putative whole amino
acid sequence (U1 protein) showed only 44.8% and 42.6% identity
to mouse ST6GalNAc IV [11] and ST6GalNAc III [11]. We con-
structed multiple alignments with sialyl motifs L and S of 16 sialyl-
transferases [11^16] and U1 protein, to predict which substrate spe-
ci¢cities it exhibits. The phylogenetic tree was constructed with the
neighbor joining method [17] which had been applied for construction
of the fucosyltransferase family in our previous study [18].
2.5. Plasmid construction of the isolated U1 cDNA clone for expression
of the soluble form enzyme
U1 cDNA was subcloned into our prepared expression vector
pcDSA [9,13,19], for the purpose of detecting accurate enzyme activity
of the U1 protein as in our previous works [9^13]. The pcDSA vector
was constructed to fuse the target cDNA with the immunoglobulin M
secretory signal peptide and the protein A immunoglobulin binding
site sequentially, and the expressed soluble form protein in medium
was collected with IgG beads for the enzyme source. The soluble form
isolated cDNA was prepared by PCR ampli¢cation with primers (5P
primer YI-3: 5P-TACAGCAGCCTCGAGATGCCAGAAGG-3P, 3P
primer YI-2: 5P-CTGCCACACAGCGTGGACACC-3P) as the pBlue-
Script cDNA clone for a template. The ampli¢ed cDNA fragment was
subcloned into the pCR II vector and excised with XhoI endonuclease
enzyme with the XhoI site of the YI-3 primer and pCR II vector to
subclone into the XhoI site of pcDSA (pcDSA-U1). Twenty Wg of the
expression plasmid pcDSA-U1, the previously prepared expression
vectors pCDB8ST (mST6GalNAc III) [11], pCDR1ST (mST6GalNAc
IV) [11] and the mock transfection vector pcDSA, were transiently
transfected into COS-7 cells as in our previous works [9^13].
2.6. Acceptor substrate preparation
Asialo K1-acid glycoprotein was prepared by 0.1 N H2SO4, 85‡C
for 15 min mild acid hydrolysis of K1-acid glycoprotein [6]. The ac-
ceptor glycoproteins were lysed in Milli Q water at a concentration of
10 mg/ml. GM1b was prepared with recombinant ST3Gal I from
asialoGM1 in the same manner as in our previous report [9]. In brief,
asialoGM1 was sialylated with the secreted form of mouse ST3Gal I
in COS-7 cells and puri¢ed with preparative TLC (chloroform:metha-
nol:0.2% CaCl2 = 55:45:10).
2.7. Sialyltransferase assay
Sialyltransferase assays were performed as described previously
[6,9^11,13]. They were performed in the presence of 0.3% Triton
CF-54, 50 mM 4-morpholineethanesulfonic acid (pH 6.4), 10 mM
MgCl2, 5 mM CaCl2, 10 mM CMP-[14C]NeuAc (10.2 kBq), 1 mg/
ml glycoprotein or 0.5 mM ganglioside acceptor substrates, and en-
zyme source in a ¢nal volume of 20 Wl. When glycosphingolipid sub-
strates were used, they were subjected to HPTLC with two solvent
systems, chloroform:methanol:0.2% CaCl2 = 55:45:10 and chloro-
form:methanol:2.5 N NH4OH = 60:40:9. When glycoprotein sub-
strates were used, the reaction mixtures were applied on SDS-PAGE
(5^20% acrylamide gel).
TLC immunostaining was performed according to Myoga et al. [20]
with the primary antibody KA17 speci¢c for GD1K for 90 min at
room temperature.
2.8. Identi¢cation of linkage between sialic acid and acceptor glycosyl
residues
Using sequential sialidase treatments as previously described [6,11],
we identi¢ed the linkage between the acceptor glycosyl residues and
sialic acid on the product of the sialyltransferase assay. By the
pcDSA-U1 expressed in media of transfected COS-7 cells, [14C]NeuAc
incorporating GM1b was prepared. [14C]NeuAc incorporating GM1b
was subjected to sequential digestion with linkage speci¢c sialidases,
Newcastle disease virus (NDV) sialidase [21] (speci¢c for K2,3- and
K2,8-linkage; Oxford Glycosystems Ltd., Bedford, MA, USA), NA-
Nase I (speci¢c for K2,3-linkage; NeuAc Linkage Analysis Kit, Glyco,
Inc., Novato, CA, USA), and Vibrio cholerae sialidase [22] (speci¢c
for K2,3-, K2,6- and K2,8-linkage; Boehringer Mannheim Co. Japan,
Tokyo, Japan).
2.9. Northern blot analysis
Ten Wg total RNAs or 2 Wg poly(A) fraction RNAs was separated
on 1.0% agarose-formaldehyde gel, then transferred onto a membrane
(Optitran BA-S 85 Reinforced NC; Schleicher and Schuell, Dassel,
Germany). The ST6GalNAc V BamHI-EcoRI fragment (449^1608)
radiolabeled with High Prime (Boehringer Mannheim) was used for
the probe. Using QuikHyb Hybridization Solution (Stratagene), hy-
bridization was performed and membranes were washed according to
the instruction manual.
2.10. Identi¢cation of CAG repeat numbers in inbred mouse strains
The isolated cDNA included CAG repeat in the ORF, which en-
coded polyglutamine. To know beforehand whether the CAG repeat
numbers are polymorphic or not among mouse strains, three inbred
mouse strains (C3H, B6-N and B6-J) were investigated. Total RNAs
were prepared from forebrain as described above and RT-PCR was
performed with the primer set YI-1 and YI-2. PCR products were
puri¢ed and the nucleotide sequence determined.
3. Result
3.1. Identi¢cation and sequence of a new sialyltransferase
cDNA clones from mice
A BLAST search was performed with the sialyl motif S and
L amino acid sequences of the ST6GalNAc family, and then
AU035329 and AA462934 were re¢ned to contain a partial
cDNA sequence of the new sialyltransferase gene. They con-
tained a putative amino acid sequence similar to ST6GalNAc
IV sialyl motif L. Using corresponding cDNA fragments, we
succeeded in isolating four independent clones from a previ-
ously prepared adult ICR mouse brain cDNA library. All of
the clones had a 2.8 kb cDNA insert (cDNA clone U1; Fig. 1)
and contained a 1005 bp ORF whose start codon was as-
signed by Kozak consensus sequence encoding a protein. A
polyadenylation signal AATAAA 185 nucleotide upstream
from the poly(A) sequence is present at the 3P end. The pu-
tative U1 protein indicated a molecular mass of 38.3 kDa and
had a hydrophobic cluster (underlined uppercase in Fig. 1) in
the amino-terminal region according to the hydropathy pro¢le
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by the Kyte and Doolittle method [23]. The putative U1 pro-
tein showed type II membrane protein topology with a short
cytoplasmic tail, a transmembrane spanning domain (21 ami-
no acid peptide in this protein), a long stem region and a large
enzyme active domain the same as other glycosyltransferases
(Fig. 1) [24]. It showed 42.6% identity to mouse ST6GalNAc
III, and 44.8% to mouse ST6GalNAc IV, but no other
showed a similarity of more than 30%. We constructed a
multiple alignment with the sialyl motifs S and L of 17 sialyl-
transferases including the putative U1 protein. ST6GalNAc
III, ST6GalNAc IV and putative U1 protein form one group
out of the other sialyltransferases on the constructed phylo-
genetic tree (data not shown) and these results indicated that
it was the ¢fth member of the ST6GalNAc subfamily.
3.2. Cloned cDNA acceptor substrate speci¢city
The COOH-terminal portion of U1 was fused with the IgG
binding domain in an expression plasmid (pcDSA-U1) and
expressed in media to determine the enzymatic activity.
pcDSA-U1 exhibited strong activity toward GM1b (Fig. 2A)
but not toward any other glycolipids and glycoproteins (Fig.
2A) (paragloboside, asialo-GM1, GM1a, GD1a, GD1b,
GT1b, GM3, asialofetuin, mucin from bovine submaxillary
gland, asialomucin from bovine submaxillary gland, holo-
transferrin and asialotransferrin). The faint activity toward
fetuin, K1-acid glycoprotein and asialo-K1-acid glycoprotein
were detected at relative activity levels of 8%, 2% and 4%,
respectively, of the activity toward GM1b. The activity to-
ward GM1b was not detected in the absence of 10 mM MgCl2
and 5 mM CaCl2. Based on the following result, we assigned
the [14C]NeuAc transferred GM1b by pcDSA-U1 for GD1K.
pCDB8ST (mST6GalNAc III) and pCDR1ST (mST6GalNAc
IV) can also transfer from NeuAc-CMP to the 6-position of
GalNAc glycoside residues on GM1b or fetuin, and we have
proved that they synthesize GD1K from GM1b [11]. These
GD1K synthetic activities are visualized and con¢rmed with
HPTLC and BAS2000 imaging analyzer in Fig. 2B. Both
[14C]NeuAc incorporated GM1b by pcDSA-U1 and by two
GD1K synthase positioned in the same area using two solvent
systems, chloroform:methanol:0.2% CaCl2 = 55:45:10 (Fig.
2B) and chloroform:methanol:2.5 N NH4OH = 60:40:9
(data not shown). The TLC plates were continuously sub-
jected to TLC immunostaining, and [14C]NeuAc incorporat-
ing GM1b by pcDSA-U1 was stained with mAb KA17 spe-
ci¢c for GD1K [8], the same as by mST6GalNAc III and
mST6GalNAc IV (Fig. 2B). Thus, we demonstrated that a
new sialyltransferase synthesized GD1K from GM1b and
was a new GD1K synthase. As regards Vmax, the substrate
speci¢cities of mST6GalNAc III, IV and V were di¡erent
from glycoprotein and glycolipid, respectively. mST6GalNAc
III and IV exhibited 80% and 500% relative activity toward
fetuin as compared to the incorporation of [14C]sialic acids
into GM1b as a substrate but mST6GalNAc V exhibited
Fig. 1. Nucleotide and deduced amino acid sequence of ICR mouse
ST6GalNAc V. The whole nucleotide sequence is described in acces-
sion number AB028840. The nucleotide and amino acid sequences
of mouse ST6GalNAc V are numbered from the presumed start co-
don and initiation methionine, respectively. The deduced transmem-
brane domain is underlined, and CAG repeats are boxed. Bold italic
shows sialyl motif L and bold italic underlined indicates sialyl motif
S.
Fig. 2. Enzyme acceptor speci¢city of mST6GalNAc V Incorpora-
tion of [14C]NeuAc into glycosphingolipids by cloned sialyltransfer-
ase. The resulting glycosphingolipids were analyzed by HPTLC with
a solvent system of chloroform:methanol:0.2% CaCl2 = 55:45:10.
The radioactive materials were visualized with a BAS 2000 radio
image analyzer (A1, B1), with orcinol-H2SO4 (A2, B2) and immu-
nostained with mAb KA17 speci¢c for GD1K (B3). A: Enzyme ac-
tivity in relation to several glycosphingolipids (GM1a, GD1a,
GD1b, GT1b, GM3, GM1b). The enzyme source was prepared
from the culture media from mST6GalNAc V (pcDSA-mST6Gal-
NAc V) transfected COS-7 cells. B: Enzyme activity of ST6GalNAc
III (pCDB8ST), ST6GalNAc IV (pCDR1ST) and mST6GalNAc V
(pcDSA-mST6GalNAc V) toward GM1b. [14C]NeuAc incorporating
GM1b was con¢rmed for GD1K by TLC immunostaining with
mAb KA17 speci¢c for GD1K (B3).
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only 8% relative activity toward fetuin. The sequential linkage
analysis for [14C]NeuAc incorporating GM1b indicated that
[14C]NeuAc was incorporated into GM1b with K2,6-linkage.
NDV sialidase treatment, speci¢c for K2,3- or K2,8-linkage
[21], was no longer e¡ective, and NANase I treatment, speci¢c
for K2,3- linkage, resulted in only two radioactive bands with-
out total radioactivity reduction. On the contrary, V. cholerae
sialidase treatment, which exhibits activity for K2,3-, K2,6-
and K2,8-linkage [22], reduced total radioactivity (data not
shown). Therefore, these result strongly suggest that the in-
corporated sialic acids contained K2,6-linkage but not either
K2,3- or K2,8-linkage. Thus, we named U1 mST6GalNAc V.
The 2780 bp nucleotide sequence of mST6GalNAc V cDNA
was registered by us in DDBJ/EMBL/GenBank with the ac-
cession number AB028840.
3.3. Expression of the ST6GalNAc V gene in mouse tissues
The expression of the ST6GalNAc V gene was examined in
several mouse tissues with Northern blot analysis. Four strong
bands corresponding to about 7 kb, 5 kb, 3 kb and 2 kb were
detected in adult mouse forebrain. A moderately intense single
signal was detected in cerebellum (Fig. 3). The other tissues
showed no signal. The same result was obtained from poly(A)
RNA enriched fractions (data not shown).
3.4. Polymorphism of CAG repeats number
To determine whether CAG repeat numbers were common
in inbred mouse strains, we performed RT-PCR with YI-1
and YI-2 primers and determined the nucleotide sequence of
the ampli¢ed fragment. The inbred mouse strains C3H, B6-N
and B6-J possessed 12, 11 and 10 CAG repeats, respec-
tively.
4. Discussion
The ¢fth type of K2,6-sialyltransferase (mST6GalNAc V)
was successfully cloned from a mouse brain cDNA library,
which exhibited GD1K synthetic activity from GM1b.
mST6GalNAc V exhibited 42.6% and 44.8% identity at the
amino acid level to mST6GalNAc III and IV, respectively. A
phylogenetic tree constructed by the neighbor joining method
revealed that mST6GalNAc V belongs to the ST6GalNAc
family, and is especially closely related to ST6GalNac III
and V (data not shown). mST6GalNAc cDNA encoded a
protein of 335 amino acids, which contained highly conserved
regions, sialyl motifs L and S, the same as other sialyltrans-
ferases so far cloned. The mST6GalNAc V gene was highly
expressed in adult mouse forebrain and moderately in cerebel-
lum. No other organs tested, such as salivary gland, intestine,
liver, kidney, heart, lung, thymus, and spleen, expressed the
mST6GalNAc V gene. Four species of mRNAs (about 2.0,
2.8, 4.0 and 6.0 kb) were detected in Northern blot. The
length of all cloned cDNAs was 2.8 kb. Further analysis of
the expression of various transcripts should be performed.
Now genomic analysis is in progress. Interestingly, mST6Gal-
NAc V carried CAG repeats encoding polyglutamine in the
putative stem region, di¡erent from the other glycosyltransfer-
ases so far cloned. Moreover, the CAG repeat number of
mST6GalNAc V cDNA varied among the inbred mouse
strains of C3H (12 repeats), B6-N (11 repeats) and B6-J (10
repeats). We will examine whether the CAG repeat exists in a
human ST6GalNAc V gene or not.
The following evidence suggests that mST6GalNAc V is the
third candidate for GD1K synthase. First, the substrate spe-
ci¢city was highly restricted to GM1b. The recombinant solu-
ble mST6GalNAc V fused with protein A, expressed in cul-
ture media of COS-7 cells, exhibited activity toward GM1b,
and the product appeared at the GD1K position on HPTLC.
mST6GalNAc V did not exhibit any activity toward other
substrates we tested including glycoproteins and glycolipids.
Secondly, linkage analysis using linkage speci¢c sialidases
con¢rmed that sialic acids of the product from GM1b were
bound through K2,6-linkage.
Substrate speci¢city comparison among all cloned GD1K
synthetic activities (mST6GalNAc III, IV and V) revealed
that the three ST6GalNAcs exhibited characteristic activities
toward glycoprotein and glycolipid, respectively [11]. The
newly cloned mST6GalNAc V showed higher activity toward
glycolipid than glycoprotein in contrast with mST6GalNAc
IV, which preferred glycoprotein rather than glycolipid.
mST6GalNAc III exhibited activity toward both glycoprotein
and glycolipid [11]. The result clearly indicates that three
GD1K synthetic enzymes possess di¡erent physiological func-
tions, and mST6GalNAc V is a most probable candidate for
GD1K synthase. mST6GalNAc V did not show GQ1bK syn-
thetic activity from GT1b. The result indicates that the other
K2,6-sialyltransferase synthesizes GQ1bK from GT1b [25].
The mST6GalNAc V gene was highly expressed as compared
with mST6GalNAc III and IV genes, as previously reported in
our data [11]. Otherwise, GD1K expression in the adult mouse
central nervous system is extremely low [8]. The kinetic anal-
ysis of divalent cation requirement revealed divalent cation is
essential for mST6GalNAc V activity. The contradiction be-
tween expression levels of gene expression and GD1K may be
caused by the divalent cation requirement in vivo. Further
Fig. 3. Northern blot analysis of ST6GalNAc V gene transcription.
RNAs from various B6-N Crj mouse tissues were separated on
agarose gel and then transferred onto nitrocellulose membrane. Hy-
bridization was performed as described in Section 2. Each 10 Wg of
total RNA was examined to detect ST6GalNAc V transcription
with 32P-labeled BamHI-EcoRI digest fragment from isolated cDNA
clone (upper panel). Lower panel is ethidium bromide staining.
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analysis of the enzyme kinetics is necessary. Analyses of gene
expression and kinetic properties of ST6GalNAc III, IV and
V will help to understand more about the physiological func-
tion of GD1K.
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